CTOs on the Move


 
At DocRX we help doctors and hospitals become more efficient, and profitable. We also help make them compliant with regulations. Visit us today!
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.docrx.com
  • 4636, Bit and Spur Road
    Mobile, AL USA 36608
  • Phone: 877.362.7991

Executives

Name Title Contact Details

Similar Companies

Novacea

Novacea, Inc. is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Santen

At Santen, we`re innovating therapies to improve the quality of life for patients worldwide. Our single focus in ophthalmology enables us to challenge unmet needs in the field—through passionate research, successful collaboration, and clarity of commitment. With over 120 years of investigative insight, Santen remains committed to the discovery, exploration, and development of ophthalmic therapies. Now, and into the future. As a global company, Santen is often expanding to accommodate new and evolving initiatives in ophthalmic research, regulatory management, production, marketing, or distribution. Our clinical development network now spans three continents, with centers in EMEA (Europe, the Middle East and Africa), Japan, and the United States.

Elligo Health Research

Elligo Health Research helps speed new therapies to market by providing large numbers of patients and clinicians the opportunity to participate in clinical research. Elligo enables rapid and effective clinical trial enrollment and facilitates the study site operations so that clinicians can focus on their research. Our unique direct to patient model allows us to streamline patient identification and qualification, site activation, patient enrollment, study initiation and study conclusion for more efficient and cost-effective trials.

SpineSmith

Dedicated to researching and developing next generation medicine.

Sagimet

Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat important diseases such as the liver disease NASH and specific cancers, with focus on targeting dysfunctional metabolic pathways. The company has unique expertise in FASN biology and has created a platform of proprietary FASN inhibitors.